ConductScience.org, home
A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease
API referenceFor AI assistants

Trial · NCT03019289

Results by group24

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 24

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Sigma-1 Receptor OccupancyA: Cohort 1: P90 + (S)-(-)-FPD; HV91.21Full Range 88.82 to 95.67percentage of receptor occupancy
Sigma-1 Receptor OccupancyA: Cohort 2: P45 + (S)-(-)-FPD; HV87.19Full Range 87.19 to 87.19percentage of receptor occupancy
Sigma-1 Receptor OccupancyA: Cohort 2: P22.5 + (S)-(-)-FPD; HV86.67Full Range 84.06 to 89.24percentage of receptor occupancy
Sigma-1 Receptor OccupancyA: Cohort 3: P5 + (S)-(-)-FPD; HV77.96Full Range 76.75 to 79.16percentage of receptor occupancy
Sigma-1 Receptor OccupancyA: Cohort 7: P1 + (S)-(-)-FPD; HV41.77Full Range 41.77 to 41.77percentage of receptor occupancy
Sigma-1 Receptor OccupancyA: Cohort 7: P0.5 + (S)-(-)-FPD; HV17.55Full Range 17.55 to 17.55percentage of receptor occupancy
Sigma-1 Receptor OccupancyA: Cohort 6; P90 + (S)-(-)-FPD; HD87.37Full Range 80.36 to 93.23percentage of receptor occupancy
Maximum Plasma Concentration of PridopidineA: Cohort 1: P90 + (S)-(-)-FPD; HV552Full Range 496 to 614ng/mL
Maximum Plasma Concentration of PridopidineA: Cohort 2: P45 + (S)-(-)-FPD; HV307Full Range 307 to 307ng/mL
Maximum Plasma Concentration of PridopidineA: Cohort 2: P22.5 + (S)-(-)-FPD; HV147Full Range 117 to 184ng/mL
Maximum Plasma Concentration of PridopidineA: Cohort 3: P5 + (S)-(-)-FPD; HV25.9Full Range 16.1 to 41.8ng/mL
Maximum Plasma Concentration of PridopidineA: Cohort 7: P1 + (S)-(-)-FPD; HV2.90Full Range 2.90 to 2.90ng/mL
Maximum Plasma Concentration of PridopidineA: Cohort 7: P0.5 + (S)-(-)-FPD; HV1.33Full Range 1.33 to 1.33ng/mL
Maximum Plasma Concentration of PridopidineA: Cohort 6; P90 + (S)-(-)-FPD; HD764Full Range 666 to 877ng/mL
Maximum Plasma Concentration of PridopidineB: Cohort 4: P90 + FPD; HV452Full Range 244 to 724ng/mL
Time to Reach Maximum (Peak) Concentration (Tmax)A: Cohort 1: P90 + (S)-(-)-FPD; HV1.97Full Range 1.50 to 3.00hours
Time to Reach Maximum (Peak) Concentration (Tmax)A: Cohort 2: P45 + (S)-(-)-FPD; HV1.98Full Range 1.98 to 1.98hours
Time to Reach Maximum (Peak) Concentration (Tmax)A: Cohort 2: P22.5 + (S)-(-)-FPD; HV1.00Full Range 0.75 to 1.50hours
Time to Reach Maximum (Peak) Concentration (Tmax)A: Cohort 3: P5 + (S)-(-)-FPD; HV1.00Full Range 0.75 to 1.50hours
Time to Reach Maximum (Peak) Concentration (Tmax)A: Cohort 7: P1 + (S)-(-)-FPD; HV1.98Full Range 1.98 to 1.98hours

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03019289/results

API referenceFor AI assistants